Predictors of long-term survival in node-positive gastric carcinoma patients with curative resection
- PMID: 17089174
- DOI: 10.1007/s00423-006-0114-9
Predictors of long-term survival in node-positive gastric carcinoma patients with curative resection
Abstract
Background and aims: We analyzed the clinicopathologic features of node-positive gastric carcinoma patients who were long-term survivors (5 years or longer) and evaluated the predictive factors associated with long-term survival.
Patients and methods: Of 554 node-positive gastric carcinoma patients with curative resection, 161 (29.1%) were long-term survivors, and 393 died of the disease before 5 years.
Results: The long-term survivor group had a recurrence rate of 16.1%, while the recurrence rate was 95.4% in the short-term survivor group (P < 0.05). The mean tumor size in the long-term survivors (4.5 cm) was significantly smaller than that in the short-term survivors (5.3 cm; P < 0.001). A depth of invasion greater than T3 was found more frequently in the short-term survivor group (88.1%) than in the long-term survivor group (70.1%; P < 0.001). Using Cox's proportional hazard regression model, the only factor found to be an independent, statistically significant prognostic parameter was tumor size (risk ratio, 0.301; 95% confidence interval, 0.10-0.88; P < 0.05).
Conclusion: The tumor size emerged as the only independent, significant factor for the prediction of long-term survival in node-positive gastric carcinoma patients with curative resection.
Similar articles
-
Multivariate prognostic study on node-positive gastric cancer: is tumor size a prognostic indicator?Hepatogastroenterology. 2012 Mar-Apr;59(114):623-6. doi: 10.5754/hge11455. Hepatogastroenterology. 2012. PMID: 22024039
-
Predictors of long-term survival in large gastric carcinoma patients.Hepatogastroenterology. 2011 Nov-Dec;58(112):2162-5. doi: 10.5754/hge09129. Hepatogastroenterology. 2011. PMID: 22234086
-
Clinicopathologic factors associated with recurrence and long-term survival in node-negative advanced gastric cancer patients.Rev Esp Enferm Dig. 2019 Feb;111(2):111-120. doi: 10.17235/reed.2018.5829/2018. Rev Esp Enferm Dig. 2019. PMID: 30404528
-
Prognostic predictors of patients with carcinoma of the gastric cardia.Hepatogastroenterology. 2012 May;59(115):930-3. doi: 10.5754/hge09356. Hepatogastroenterology. 2012. PMID: 22469742
-
Multivariate prognostic study on large gastric cancer.J Surg Oncol. 2007 Jul 1;96(1):14-8. doi: 10.1002/jso.20631. J Surg Oncol. 2007. PMID: 17582596 Review.
Cited by
-
Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: a meta-analysis.World J Gastroenterol. 2012 Dec 28;18(48):7384-93. doi: 10.3748/wjg.v18.i48.7384. World J Gastroenterol. 2012. PMID: 23326149 Free PMC article.
-
Gastric cancer: Where is the place for the surgeon, the oncologist and the endoscopist today?World J Gastrointest Oncol. 2011 Jan 15;3(1):10-3. doi: 10.4251/wjgo.v3.i1.10. World J Gastrointest Oncol. 2011. PMID: 21267398 Free PMC article.
-
Expression levels of microRNA-192 and -215 in gastric carcinoma.Pathol Oncol Res. 2012 Jul;18(3):585-91. doi: 10.1007/s12253-011-9480-x. Epub 2011 Dec 29. Pathol Oncol Res. 2012. PMID: 22205577
-
Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance.J Gastrointest Surg. 2010 Jul;14(7):1170-9. doi: 10.1007/s11605-010-1202-2. Epub 2010 Apr 27. J Gastrointest Surg. 2010. PMID: 20422307
-
Neoadjuvant Therapy of Gastric Cancer: A Decisive Step Forward.Gastrointest Tumors. 2014 Jun;1(2):99-104. doi: 10.1159/000362577. Epub 2014 May 9. Gastrointest Tumors. 2014. PMID: 26675677 Free PMC article. Review.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical